Arcutis Biotherapeutics, Inc.ARQTEarnings & Financial Report
Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.
Revenue
$81.5M
Gross Profit
$74.0M
Operating Profit
$-14.6M
Net Profit
$-15.9M
Gross Margin
90.8%
Operating Margin
-17.9%
Net Margin
-19.5%
YoY Growth
164.1%
EPS
$-0.13
Arcutis Biotherapeutics, Inc. Q2 FY2025 Financial Summary
Arcutis Biotherapeutics, Inc. reported revenue of $81.5M (up 164.1% YoY) for Q2 FY2025, with a net profit of $-15.9M (up 69.6% YoY) (-19.5% margin). Cost of goods sold was $7.5M, operating expenses totaled $88.6M.
Key Financial Metrics
| Total Revenue | $81.5M |
|---|---|
| Net Profit | $-15.9M |
| Gross Margin | 90.8% |
| Operating Margin | -17.9% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Arcutis Biotherapeutics, Inc. Q2 FY2025 revenue of $81.5M breaks down across 3 segments, led by ZORYVE Foam at $39.2M (48.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| ZORYVE Foam | $39.2M | 48.1% |
| ZORYVE Cream0.3 | $27.7M | 34.0% |
| ZORYVE Cream0.15 | $14.6M | 17.9% |
Arcutis Biotherapeutics, Inc. Annual Revenue by Year
Arcutis Biotherapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $376.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $376.1M |
| 2024 | $196.5M |
Arcutis Biotherapeutics, Inc. Quarterly Revenue & Net Profit History
Arcutis Biotherapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $129.5M | +81.5% | $17.4M | 13.4% |
| Q1 FY2026 | $105.4M | +60.1% | $-11.3M | -10.7% |
| Q4 FY2025 | $129.5M | +81.5% | $17.4M | 13.4% |
| Q3 FY2025 | $99.2M | +121.7% | $7.4M | 7.5% |
| Q2 FY2025 | $81.5M | +164.1% | $-15.9M | -19.5% |
| Q1 FY2025 | $65.8M | +32.8% | $-25.1M | -38.1% |
| Q4 FY2024 | $71.4M | +427.6% | $-10.8M | -15.1% |
| Q3 FY2024 | $44.8M | +17.4% | $-41.5M | -92.8% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.8M | $71.4M | $65.8M | $81.5M | $99.2M | $129.5M | $105.4M | $129.5M |
| YoY Growth | 17.4% | 427.6% | 32.8% | 164.1% | 121.7% | 81.5% | 60.1% | 81.5% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $437.4M | $348.9M | $344.1M | $352.4M | $371.0M | $433.0M | $460.0M | $433.0M |
| Liabilities | $280.7M | $191.3M | $201.4M | $213.5M | $212.9M | $243.5M | $270.4M | $243.5M |
| Equity | $156.6M | $157.5M | $142.7M | $139.0M | $158.1M | $189.5M | $189.6M | $189.5M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-34.7M | $-748000 | $-30.4M | $324000 | $-1.8M | $26.2M |